Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector
Colorectal Cancer
Explore 714 assets in Colorectal Cancer →Floatz Rating
C34/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
vaccine
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
25High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06149481CT.gov Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) | — | Recruiting | — | — | — |
NCT03169777CT.gov QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC | — | Withdrawn | — | — | — |
NCT00924092CT.gov An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ... | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector (this asset) | National Cancer Institute (NCI) | P1/2 | C · 34 |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BBB |
| Marble Dust | James Varani | P2/3 | BB |
| Oxaliplatin | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | P4 | BB |
| Fluorouracilum | UNICANCER | P4 | BB |
| Orectalip | Sinphar Pharmaceutical Co., Ltd | P4 | BB |
| Irinotecan | UNICANCER | P4 | BB |
| Levofolinic Acid | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | P3 | BB |
| Fentanyl | Mansoura University | P4 | BB |
+42 more in the Colorectal Cancer cohort
Other indications for Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Triple-Negative Breast Carcinoma | — | P2 | CC · 41 |
| Malignant Pancreatic Neoplasm | — | P2 | C · 36 |
| Hepatocellular Carcinoma | — | P1/2 | C · 33 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Therapeutic Cancer Vaccine Genetically Modified To Express Recombinant Carcinoembryonic Antigen (Cea) Protein, Using Heat-Killed Yeast (Saccharomyces Cerevisiae) As A Vector in Colorectal Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/therapeutic-cancer-vaccine-genetically-modified-to-express-recombinant-carcinoembryonic-antigen-cea-protein-using-heat-killed-yeast-saccharomyces-cerevisiae-as-a-vector-colorectal-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →